Drug Trial Radar · NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
512
Planned (sponsor's estimate)
Start
Oct 26, 2022
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Summit Therapeutics; AVEO Pharmaceuticals, Inc.
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.
Conditions
- Clear Cell Renal Cell Carcinoma
- Solid Tumors
Interventions
CasdatifanDrug
Administered as specified in the treatment arm
CabozantinibDrug
Administered as specified in the treatment arm
ZimberelimabDrug
Administered as specified in the treatment arm
IpilimumabDrug
Administered as specified in the treatment arm
TivozanibDrug
Administered as specified in the treatment arm
IvonescimabDrug
Administered as specified in the treatment arm
AxitinibDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 4 months
- Number of participants with adverse events (AEs)Time frame: Up to 4 months
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
Santa Monica, California · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
New Orleans, Louisiana · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Camperdown, Australia · Not yet recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Sydney, Australia · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.